Nanocarrier vaccines for SARS-CoV-2

Adv Drug Deliv Rev. 2021 Apr:171:215-239. doi: 10.1016/j.addr.2021.01.002. Epub 2021 Jan 9.

Abstract

The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.

Keywords: COVID-19 vaccine; Nanovaccine; SARS-CoV-2; mRNA vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / administration & dosage*
  • COVID-19 Vaccines / immunology
  • Drug Carriers / administration & dosage*
  • Drug Delivery Systems / methods
  • Drug Delivery Systems / trends
  • Humans
  • Nanocapsules / administration & dosage*
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / immunology
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology

Substances

  • COVID-19 Vaccines
  • Drug Carriers
  • Nanocapsules
  • Viral Vaccines